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Abstract. Plasmodium vivax accounts for an increasing fraction of malaria infections in Thailand and Cambodia. We
compared P. vivax genetic complexity and antimalarial resistance patterns in the two countries. Use of a heteroduplex
tracking assay targeting the merozoite surface protein 1 gene revealed that vivax infections in both countries are
frequently polyclonal (84%), with parasites that are highly diverse (HE = 0.86) but closely related (GST = 0.18). Following
a history of different drug policies in Thailand and Cambodia, distinct patterns of antimalarial resistance have emerged:
most Cambodian isolates harbor the P. vivax multidrug resistance gene 1 (pvmdr1) 976F mutation associated with
chloroquine resistance (89% versus 8%, P < 0.001), whereas Thai isolates more often display increased pvmdr1 copy
number (39% versus 4%, P < 0.001). Finally, genotyping of paired isolates from individuals suspected of suffering relapse
supports a complex scheme of relapse whereby recurrence of multiple identical variants is sometimes accompanied by
the appearance of novel variants.
INTRODUCTION
Plasmodium vivax accounts for an increasing fraction of
malaria cases in Thailand and Cambodia.1–3 It is now recog-
nized that P. vivax poses a greater challenge to malaria elim-
ination in the region, largely caused by its propensity for
relapse.4,5 Little is known about the transmission dynamics of
vivax parasites in Southeast Asia and their evolving drug
resistance patterns. Molecular tools can provide insights into
these processes by evaluating the diversity of parasites and
assessing for polymorphisms correlated with drug resistance.
They also have the potential to identify genotypic patterns
of relapsing parasites.6 These data can provide a framework
for monitoring control efforts and informing interventions
targeted at elimination.
The interplay between malaria genetic diversity, multiplic-
ity of infection (MOI), and emergence of drug resistance is
complex. The MOI is the number of parasite clones found
simultaneously within a host, a measure of within-host genetic
complexity. While parasite diversity on a population scale
allows for resistant parasite populations to expand under drug
pressure, in-host diversity impacts the development of drug
resistance by affecting sexual recombination rates and allowing
competitive suppression among co-infecting drug-resistant and
drug-sensitive clones.7,8
Previous studies have shown high genetic diversity but lim-
ited MOI among P. vivax infections in Southeast Asia.9–12
However, the genotyping methods used in these studies are
often limited in their ability to detect minority clones, leading
to an underestimation of MOI.8 The heteroduplex tracking
assay (HTA) is a genotyping technique that has proven adept
at uncovering minority variants within malaria infections and
in infections with other agents.13–16 Thus, it provides a more
accurate picture of within-host genetic diversity.17 It also facil-
itates the tracking of clones within hosts over time, potentially
providing a nuanced portrait of relapsing vivax populations.18
Additionally, there is concern for emerging chloroquine-
resistant vivax in Southeast Asia; however, reports concern-
ing putative vivax drug resistance genes remain limited. Studies
of P. vivax multidrug resistance gene 1 (pvmdr1), the vivax
analogue to the multidrug resistance gene found in P. falciparum,
have linked a polymorphism (Y976F) in this gene to chloro-
quine resistance, whereas an increased copy number of the
gene is associated with increased susceptibility to chloroquine
and reduced susceptibility to mefloquine, amodiaquine, and
artesunate in vitro.19–22 Variable prevalence of mutant single
nucleotide polymorphisms (SNPs) and copy number increases
in pvmdr1 have been reported from Thailand, however little
comparative data has been published from Cambodia.19,21–26
Because this region has played an important role in the evo-
lution of drug-resistant falciparum malaria, a better under-
standing of the distribution of vivax drug resistance alleles in
the parasite populations is needed.
In this report, we use an HTA and nested polymerase chain
reaction (nPCR) assay for P. vivax merozoite surface protein
1 (pvmsp1), a real-time PCR assay for pvmdr1 copy number,
and pvmdr1 sequencing on parasite isolates from Thailand
and Cambodia to determine: 1) the relative genetic diver-
sity and multiplicity of infection of P. vivax infections in
these regions, 2) differences in the patterns of molecular
markers of antimalarial resistance between the two countries,
and 3) genotype patterns of paired initial and recurrent vivax
infections in Cambodia. Together, these data provide a com-
parative view of drug resistance patterns and the genetic fac-
tors that may shape the future development of drug resistance
in these areas.
MATERIALS AND METHODS
Patient samples. Filter paper blood spots from vivax patients
were acquired from clinical studies carried out in northwest-
ern Thailand and southern Cambodia. Vivax malaria cases
occur throughout the year in both locales, but most cases
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occur during the rainy season. Thai samples (N = 50) were
collected from patients presenting to public health clinics in
the Mae Sod district of Tak Province between February and
June 2009. Cambodian samples were collected between August
2006 and December 2007 as part of a chloroquine treatment
trial at the Chumkiri health center in Kampot Province.27
Details of the study have previously been published. Anti-
relapse therapy with primaquine was not given. One hundred
and ten (110) subjects were enrolled, 45 of whom developed
recurrent infection within the 42-day follow-up. One hundred
and nine (109) enrollment isolates and 44 recurrent isolates
were available for study.
Ethics statement. Written informed consent was obtained
from all participants, with approval from the ethics commit-
tees of Walter Reed Army Institute of Research, the Naval
Medical Research Unit 2 (Jakarta, Indonesia), the Ministry of
Public Health in Thailand (Bangkok, Thailand), the National
Ethics Committee forHealthResearch (PhnomPenh, Cambodia),
and the University of North Carolina.
HTA tracking assay and nPCR of pvmsp1. The strategy
used to develop the pvmsp1 HTA was based on that previ-
ously used to develop HTAs for Plasmodium falciparum.13,17
Four radiolabeled probes targeting 500 bp of interspecies con-
served blocks (ICB) 5&6 of the Pvmsp1 gene and the variable
region in between were developed—two based on P. vivax
strains found in the MR4 repository (Nicaragua, Pakchong),
and two generated from Thai clinical samples (Th04, Th06).
The PCR products amplified using the primers and conditions
listed in Table 1 were blunt-end cloned into the pT7Blue
vector (Novagen, Inc., Madison, WI) and sequenced to con-
firm pvmsp1 insertion. Ten micrograms (10 mg) of each pvmsp1
ICB5-6 pT7Blue construct was then digested, end-labeled,
and digested again to release the 35S-labeled probes as previ-
ously described. Heteroduplexes containing 35S-labeled probe
and 8 mL of PCR-amplified ICB5-6 of Pvmsp1 from patient
samples were formed in annealing reactions and separated by
electrophoresis on a 6% polyacrylamide gel, and then exposed
to BioMax MR x-ray film (Eastman Kodak, Rochester, NY)
for 24–72 hours at room temperature.
The HTA bands were considered unique pvmsp1 sequence
variants if they were not in the single-stranded probe or probe
homoduplex lanes (Figure 1A). Because all four probes
were able to distinguish multiple minority variants in the clin-
ical samples, the Nicaragua probe (NIC) (GenBank accession
no. JN674534) was chosen for application of the HTA to the
study samples, as it was expected to contain the sequence that
was the most different from the Thai/Cambodian samples.
Supplemental Figure 1 provides a comparison of the pvmsp1
ICB5-6 probe sequence to the Sal1 and Belem strains and
several Thai sequences from GenBank.
A previously published nPCR assay targeting ~700 bp of
the same ICB5-6 region was selected as a comparison assay
for measuring MOI.29,30 The assay was carried out as previ-
ously described using Hotstar master mix (Qiagen, Valencia,
CA), 800 nM of the forward and reverse primers, and 2 mL of
parasite DNA in each reaction. The PCR products were run
on a 1.8% agarose gel with the presence of mixed genotypes
determined by size polymorphisms (Figure 1B and C). Ran-
domly selected products were also run on a 3.0% agarose gel
but did not result in a greater number of distinguished bands
per sample. Plasmid DNA containing the cloned Pvmsp1 frag-
ment of the Nicaragua strain (cat. MRA-340; MR4, Manassas,
VA) was used as a positive control for all assays.
Measuring MOI and genetic diversity. The MOI was
defined as the number of genotypic clones detected per patient
isolate by counting either the number of size variants detected
by nPCR or the number of sequence variants detected by
HTA (Figure 1). The MOI was determined by both assays on
all enrollment samples (Thai [N = 50] and Cambodian [N =
109]). To distinguish allelic variants in the HTA, the distance
migrated by each pvmsp1 variant was measured and assigned
a relative migration index (Rf). The Rf units were divided
among 20 bins of 0.05 Rf units, a method that has previously
been validated.17 When more than one band fell within the
same bin, they were assigned the same Rf. Allele frequencies
were calculated as the prevalence of a clone with a unique Rf
among the total number of clones within each geographical
cohort. The genetic diversity within each population was esti-
mated by calculating the virtual heterozygosity (HE).
8 In this
context, HE gives the average probability that two clones
taken at random from the population are different. The genetic
divergence between populations was estimated by calculating
Nei’s genetic distance (similar to the fixation index or FST)
using Genetic analysis in Excel (GenAlEx) software v6.1.31,32
Recurrent isolates were not included in these calculations to
avoid sampling bias.
Real-time PCR for Pvmdr1 copy number. A novel multi-
plex Taqman assay was developed to estimate pvmdr1 copy
Table 1
Primers and probe sequences used in the heteroduplex tracking assay (HTA) and Pvmdr1 assays
Genetic marker Primer/probe sequence Amplification program
Pvmsp1
HTA forward* 5¢-GATGGTCCTCAAAAGGGAAA 95 °C + 15¢; 35 cycles of






Copy number forward 5¢-CGATTGAAGATTCCGAAGTTG 50 °C +2¢; 95 °C + 10¢; 40
Copy number reverse 5¢-TTAGAACCCACCAGCGTTTC cycles of 95 °C + 15² and
Copy number probe 5¢-6FAM-GAAGGTGCTGATCCACGATT-MGB 60 °C + 1¢
Sequencing forward 5¢-ATAGTCATGCCCCAGGATTG 95 °C + 15¢; 35 cycles of
Sequencing reverse 5¢-CCTTTCGAAGGACAGCTTTG 95 °C + 15², 55 °C + 30²,
and 72 °C + 1¢; 72 °C + 10¢
*Primers modified from Maestre and others.28
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number using P. vivax aldolase (Pv aldolase) as the reference
gene. Aldolase primers were previously described.19 The other
primers and probes were designed with Primer Express Soft-
ware v3.0 (Applied Biosystems, Foster City, CA) (Table 1).
Real-time PCR was performed on an ABI 7300 Real-Time
PCR system (Applied Biosystems) in duplicate 20 mL reac-
tions containing Roche FastStart Universal Probe Master
mix, 800 nM of pvmdr1 forward and reverse primers, 400 nM
of pvaldolase forward and reverse primers, 100 nM of each
probe, and 2 mL of parasite DNA, with cycling conditions
listed in Table 1. Plasmids containing the cloned fragments
of pvmdr1 and pvaldolase, developed using the TOPO XL
PCR Cloning Kit (Invitrogen, Carlsbad, CA), were used as
positive controls in every experiment. Threshold cycle (Ct)
values were exported and analyzed in Microsoft Excel using
the Pfaffl method to determine copy number.33 Copy number
was determined by rounding to the nearest integer and was
considered increased if > 1.
Sequencing for Pvmdr1 mutant SNPs. Primers were
designed to amplify a 647 bp region of the pvmdr1 gene
containing the Y976F SNP and the F1076L SNP (Table 1).
The PCR amplification was carried out in 50 mL reactions
containing 5 mL of 10 + PCR buffer, 20 mM of forward and
reverse primers, of 0.2 mM dNTP, 0.25 mL of Qiagen Hotstar
taq, and 5 mL of parasite DNA with cycling conditions listed
in Table 1. The amplified products were directly sequenced by
Eton Bioscience, Inc. (Research Triangle Park, NC) (GenBank
accession nos.: JQ925719–JQ925865).
Statistical analysis. Median MOI was compared between
the two Pvmsp1 genotyping assays (HTA and nPCR) using
the Wilcoxon rank-sum test. Possible associations between
MOI and clinical features including age, gender, baseline
parasitemia, parasite clearance time in days, and pvmdr1
copy number were investigated using the Wilcoxon rank-sum
test or linear regression as appropriate. The proportion of
samples harboring increased pvmdr1 copy number or the
Y976F and F1076L mutations were compared between the
Thai and Cambodian study populations using the Pearson c2
or Fisher’s exact tests. Genotypes of initial and recurrent iso-
lates were compared for relatedness, and for MOI and pvmdr1
copy number status using paired t tests. Statistical analysis
was done using STATA v.12.0 (STATA Corp, College
Station, TX).
RESULTS
Multiplicity of infection. Compared with nPCR, the HTA
detected more polyclonal infections, revealing a high multi-
plicity of infection in both Thailand and Cambodia (Figure 1).
Of the 47 Thai isolates that successfully amplified in both
assays, 39 (83%) displayed multiple clones by HTA, whereas
only 6 (13%) displayed more than one size polymorphism by
nPCR Figure 2A, Table 2. Similarly, among the Cambodian
enrollment isolates, 92 (84%) were multiclonal by HTA ver-
sus 27 (25%) by nPCR (Figure 2B). The HTA detected up to
7 clones within single individuals, whereas nPCR very rarely
detected more than 2 clones (only 1 of 156 isolates had 3 var-
iants). The mean MOIs for the Thai and Cambodian samples
as determined by HTA were very similar: 3.0 and 2.9, respec-
tively, with a combined mean MOI of 2.9 (interquartile range
[IQR] 2–4). Among the Cambodian trial participants, no
association was found between MOI at enrollment and age,
gender, baseline parasitemia, parasite clearance time, or pvmdr1
copy number.
Pvmsp1 sequence variation and allelic diversity. In total,
15 distinct pvmsp1 alleles and 30 unique genotypes (repre-
senting combinations of allelic clones) were detected among
the 47 Thai isolates, whereas 16 unique alleles and 66 unique
genotypes were detected among the 109 Cambodian isolates
(Figure 3). Five common allelic variants accounted for 75% of
Figure 1. Representative pvmsp1 heteroduplex tracking assay (HTA) (A) and nested polymerase chain reaction (nPCR) (B, C) for selected
Thai samples. Panel A shows a representative HTA. Each lane contains bands representing the single-stranded probe and probe homoduplex
(seen in the NTC and probe alone lanes). Patient numbers are indicated at the top of each lane. Unique pvmsp1 sequence variants were identified
by counting bands that were not in the single-stranded probe or probe homoduplex lanes. These represent heteroduplexes formed between the
probe and amplified PCR products from each patient sample. Heteroduplexes can migrate both above and below the single-stranded probe and
are marked with asterisks in the figures. Panel B shows the corresponding nested PCRs for the patient samples shown in the HTA, demonstrating
that a higher number of variants was detected by HTA in most of these samples (except patient 30 who had a single variant by each method). Panel C
shows a representative gel of patient samples containing multiple variants by nPCR.
1118 LIN AND OTHERS
Thai clones, whereas six common variants accounted for 87%
of Cambodian clones. The distribution of alleles appeared sim-
ilar between the two regions. Individual allele frequencies
ranged from 0.2% (occurring once) to 28%. Based on these
allele frequencies,HE at the pvmsp1 locus was 0.86 in Thailand
and 0.86 in Cambodia, whereas Nei’s genetic distance between
the two populations was 0.18.
Pvmdr1 copy number and SNP analysis. Thai isolates were
more likely to display increased pvmdr1 copy number com-
pared with the Cambodian isolates (39% versus 4%, P <
0.001). Among the Thai samples, 61% (30 of 49) contained
one copy of pvmdr1, 33% (16 of 49) had two copies, and 6%
(3 of 49) had three copies. In contrast, only 4% (4 of 109)
of the Cambodian enrollment samples displayed increased
copy number (Figure 4). However, the 976F mutation was
much more prevalent among the Cambodian isolates. Eighty-
nine percent (83 of 93) of the enrollment samples harbored
the Y976F mutant SNP versus just 8% (2 of 26) of the Thai
samples (P < 0.001) (Figure 4). Most of the 83 Cambodian
samples that were positive for the Y976F mutation also car-
ried the F1076L mutation, making them double mutants; only
two samples were mutant at codon 976 but wild-type at 1076.
On the other hand, 62% (16 of 26) of Thai samples were
single 1076L mutants, remaining wild-type at codon 976 while
carrying the F1076L mutation.
Recurrent and relapsing genotypes. When sampling recur-
rent infections from an endemic area, it is impossible to dis-
tinguish with confidence which recurrences are relapses
versus reinfections or recrudescence from treatment failure.
However, we have previously reasoned that the majority of
the 44 recurrent parasitemias from the Cambodian study rep-
resent relapses.18 Previously, we reported the use of HTA in
this cohort to identify variants specifically associated with
relapse. However, this does not provide a complete picture
of the potentially complex nature of recurrent parasitemias.
Therefore, here we provide a more detailed examination of
the genotypic patterns associated with these recurrences as
determined by HTA. Paired isolates were classified into
different categories of relatedness based on the number of
shared variants between the initial and recurrent sample.
Recurrent genotypes were “related” if at least one of the
variants detected initially was also observed in the recurrent
isolate and “different” if none of the variants detected ini-
tially was observed in the recurrent sample. A genotype was
considered “novel” if at least one variant detected in the
recurrent sample was not detected initially. Based on this
classification system, adapted from other studies,12 the vast
majority of paired infections were related (41 of 44 or 93%),
whereas only 3 of 44 (6.8%) pairs were different (Figure 5).
Among the related pairs, 13 of 41 recurrent genotypes were
identical, 18 of 41 were not identical but did not contain any
novel variants, and 10 of 41 contained novel variants. In 29 of
41 (71%) of these related pairs, both initial and recurrent
genotypes were multiclonal.
In most of the 41 genotypic pairs that were related, at least
half of the variants in the recurrent genotype were also
detected in the initial isolate, making them highly related.
Table 2
MOI of Thai and Cambodian vivax samples detected by HTA versus





HTA nPCR HTA nPCR
Thailand 47 3.0 (2–4) 1.1 (1–1) < 0.001 83% 13%
Cambodia 109 2.9 (2–4) 1.3 (1–1) < 0.001 84% 25%
Combined 156 2.9 (2–4) 1.2 (1–1) < 0.001 84% 21%
*MOI = multiplicity of infection; HTA = heteroduplex tracking assay; nPCR = nested
polymerase chain reaction.
†Reported as mean MOI (interquartile range).
‡P value comparing MOI of HTA versus nPCR by Wilcoxon rank-sum test.
Figure 3. Frequency of pvmsp1 sequence variants in enrollment
samples by heteroduplex tracking assay (HTA) migration index
(Rf). Total N = 453 clones (142 Thai and 311 Cambodian) cor-
responding to 156 vivax infections. Five common variants accounted
for 75% of Thai clones, whereas six common variants accounted for
87% of Cambodian clones.
Figure 2. Distribution of multiplicity of infection. Number of coinfecting Pvmsp1 clones per isolate detected by nested polymerase chain reaction
(nPCR) versus heteroduplex tracking assay (HTA) among the Thai samples (N = 47) (A) and Cambodian enrollment samples (N = 109) (B).
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Twenty-six of 38 (68%) of these highly related recurrences
were multiclonal, with multiple clones matching the initial
genotype, making it unlikely that they represent reinfec-
tions. All of these pairs, suspected of being relapses, showed
either no change or a reduction in MOI from the initial to
recurrent sample.
DISCUSSION
Our study offers several important observations about the
genetic diversity, drug resistance patterns, and relapse pat-
terns of P. vivax infections in Southeast Asia. First, despite
being a region of relatively low transmission, most infections
(84%) were polyclonal with a mean MOI of 2.9, a finding
consistent between Thailand and Cambodia. This is compara-
ble to estimates of MOI in children in a hyperendemic region
of Papua New Guinea (74% multiclonal infections, mean
MOI of 2.7) determined by similarly discriminatory methods.34
This finding supports growing evidence that P. vivax complex-
ity rivals that of P. falciparum in areas where the species are
co-endemic.34,35 Previous estimates of the prevalence of mixed
strain genotypes in Thailand have come close to this level,
but have relied on typing multiple microsatellite markers,
whereas the HTA sensitively detects multiple alleles or clones
at a single locus. A limitation of the HTA is its reliance on the
migration index (Rf) to indirectly discriminate between differ-
ent sequence variants. The genetic relatedness between vari-
ants cannot be deduced as may be possible with microsatellite
variants with similar numbers of repeats. Furthermore, it is
hard to precisely compare multi-allelic genotypes across dif-
ferent gels. We grouped the pvmsp1 variants into 20 different
bins based on their Rf, but there were instances when more
than one unique band was found within one bin. Although
these bands likely represented unique clones, we assigned
them the same genotype. This binning system has the poten-
tial to underestimate MOI and allelic diversity, but we were
still able to show a great range of pvmsp1 diversity consistent
with other studies.35
Why might MOI of P. vivax in a hypoendemic region of
Southeast Asia reach the same levels as that seen in the
hyperendemic region of Papua New Guinea? Transmission
intensity is an important determinant of MOI, but factors
relating to the intrinsic biology of P. vivax likely also contrib-
ute to higher MOI in hypoendemic regions. These factors
include the contribution of vivax relapses, with the potential
for reactivation of multiple heterologous hypnozoites at the
same time. The production and circulation of gametocytes
early in P. vivax infection also leads to 1) more opportunities
for recombination when multiple gamete clones are present
and 2) individuals with multiclonal infections becoming infec-
tious before they receive antimalarial treatment that quickly
eliminates drug-sensitive clones and reduces MOI.4,12,36 The
transmission of multiple gametocyte clones at one time has
been shown in P. falciparum and is expected to be an impor-
tant contributor to MOI in areas of low transmission.37–39
Because increased MOI facilitates recombination, these forces
could allow P. vivax to maintain high genetic diversity despite
lower levels of transmission.
Second, we have shown that despite similar allelic diversity
and close kinship measured at the pvmsp1 locus within
Thailand and Cambodia, the parasites display distinct drug
resistance patterns. The HE was high for both locations,
whereasgenetic divergencebetween the twowas low, suggesting
similar genetic backgrounds. However, pvmdr1 resistance pat-
terns were markedly different: a substantial proportion of
parasites from northwestern Thailand displayed increased
copy number but few carried the 976F mutant allele, whereas
most Cambodian parasites carried the mutant allele without
increased copy number. Sampling of the Thai and Cambodian
samples in our study was not concurrent, with the Cambodian
Figure 4. Proportion of Thai versus Cambodian isolates with pvmdr1 Y976F and F1076L mutants (A, B) and increased pvmdr1 copy number
(C, D). N = 121 (26 Thai and 122 Cambodian) for sequencing data and N = 158 (49 Thai and 150 Cambodian) for copy number data. Thai isolates
were more likely to display increased copy number (39% of Thai versus 4% of Cambodian isolates with CN > 1), whereas Cambodian isolates were
more likely to carry the 976 mutant allele (89% versus 8% of Thai isolates).
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samples collected 2–3 years before the Thai samples. How-
ever, the prevalence of 976F mutants in our 2006–2007
Cambodian cohorts closely matched the prevalence found
in samples collected in 2008 from an area just north of
Chumkiri.25 No prior studies measuring pvdmr1 copy number
in Cambodia have been reported. Our Thai copy number data
show a slightly higher proportion of increased copy number
isolates (39%) than previous studies in which 7–23% (cumu-
lative 23 of 164 or 14%) of western Thai isolates collected
from 2003 to 2007 displayed increased copy number19,21,22,24;
however, our isolates were also collected later in time. The
same studies reported 9–25% prevalence of the 976F mutant,
slightly greater than the 8% prevalence in our sample. Inter-
estingly, P. falciparum isolates from Thailand show a synon-
ymous pattern of contrasting Pfmdr1 drug resistance profiles
at the Thai-Myanmar versus Thai-Cambodian borders, with
western isolates having higher mdr1copy numbers, and east-
ern isolates on the Cambodian border carrying the mutant
184F allele.40,41
Selection for different Pvmdr1 haplotypes has likely been
shaped by different drug policies in the two countries. Chlo-
roquine monotherapy was still the official drug policy for
P. vivax in Cambodia until very recently, whereas in Thailand
a combination of chloroquine and primaquine has been the
recommended regimen for over 30 years. Because primaquine
also has efficacy against blood-stage vivax parasites,42 the
Thai drug policy aimed at radical cure may have delayed the
development of chloroquine resistance by administering com-
bination therapy. Additionally, a longer history of mefloquine
therapy in Thailand, with a gradual switch from mefloquine
monotherapy to artemisinin-based combination therapy with
artesunate-mefloquine from 1995 to 2005, may have prevented
the accumulation of 976F mutants. The increased pvmdr1
copy number of Thai vivax parasites suggests that they have
responded to mefloquine drug pressure in the same fashion as
their falciparum counterparts, likely in the context of highly
prevalent mixed falciparum/vivax infections.2
The pvdmr1 profile of the Cambodian parasites in our study
resembles that of multidrug-resistant vivax in Papua New
Guinea. However, the in vivo trial from which our samples
were collected identified no vivax recurrences before Day 28
that would be suggestive of treatment failure. Unfortunately,
there is not enough evidence to determine whether the high
prevalence of double 976F/1076L pvmdr1 mutants in the
Cambodian parasites heralds increasing tolerance to chloro-
quine. It is also important to note that because all current
pvmdr1 assays are PCR based, they cannot account for the
presence of multiple clones that may have varying degrees of
drug resistance; sequences and copy numbers are likely a
reflection of the dominant clones existing within samples. As
a result of increasing evidence of rising clinical chloroquine
resistance in Cambodia, as of 2012, dihydroartemisinin-
piperaquine has been adopted by the National Malaria Pro-
gram for treatment of all malaria species, whether P. falciparum
or P. vivax.
As opposed to prior studies of vivax relapses, which have
concluded that approximately two-thirds of vivax relapses in
adults display different genotypes from the initial primary
infection,12,29,43 we found high degrees of relatedness in
paired initial and recurrent isolates from Cambodia when
accounting for minority variants at a single locus. The HTA
was highly discriminatory at pvmsp1 (HE 0.86), but still showed
frequent recurrence of multiple variants matching the initial
genotype. Similarly, when de Araujo and others44 accounted for
rare alleles detected by sequencing 10 microsatellite markers,
they found that 88% of relapses met their definition of homolo-
gous relapse. Our relapse data are limited by the inability to
distinguish with confidence which recurrences are relapses ver-
sus reinfections or recrudescence when sampling persons in
an endemic setting. However, as discussed elsewhere in more
depth, the lack of primaquine dosing in these persons, com-
bined with the timing of recurrences after treatment (between
Day 35 and Day 42), and the overall low incidence of malaria
in the area lead us to believe that relapses comprised a signif-
icant proportion of the recurrences we studied.18
If the recurrence of multiple identical variants matching the
initial genotype identifies a relapse as we suspect, our findings
support a highly complex scheme of relapse. In initial infec-
tions with multiple genetically distinct vivax clones, all or a
Figure 5. Categories of relatedness for 44 paired initial and recur-
rent vivax parasitemias. Genotypic patterns of 44 paired isolates from
persons with recurrent vivax infection were categorized as related (at
least one of the variants detected in the initial sample was observed in
the recurrent sample), different (none of the variants detected in the
initial sample was observed in the recurrent sample), or novel (at
least one variant detected in the recurrent sample was not detected
in the initial sample). The majority of genotypic pairs were related
(93% or 41 of 44). In 29 of 41 (71%) of these related pairs, both initial
and recurrent genotypes were multiclonal. Representative examples
are diagrammed in the lower panel.
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subset of these multiple clones can reactivate simultaneously
to cause relapse. At the same time, 30% of recurrent samples
showed novel variants, suggesting that latent hypnozoites
unrelated to the initial infection may also be reactivated at
the time of relapse. Together, a picture of reactivation of
multiple homologous hypnozoites, sometimes accompanied
by heterologous hynozoites, emerges. This schema of relapse
could help explain the high MOI we observed among vivax
parasites in the region.
CONCLUSIONS
We have used a range of molecular assays to characterize P.
vivax populations from Thailand and Cambodia, including
those causing relapse. Together, these assays have drawn a
portrait of 1) high genetic diversity both within and among
hosts, rivaling that of P. falciparum; 2) different resistance
profiles among parasites in Thailand versus Cambodia shaped
by unique drug pressures within the two countries; and
3) frequent relapses caused by multiclonal populations that
are related to preceding infections. These findings expand
our knowledge of the unique factors influencing the develop-
ment of drug-resistant vivax and provide insight into poten-
tial barriers to malaria elimination in Southeast Asia.
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